Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A three-phase study designed to test the efficacy, tolerability and safety of the combination of ziprasidone with selective serotonin reuptake inhibitors (SSRI) for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs.

Next Previous
Trial Profile

A three-phase study designed to test the efficacy, tolerability and safety of the combination of ziprasidone with selective serotonin reuptake inhibitors (SSRI) for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 02 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 03 May 2013 Lead trial centres amended as reported by ClinicalTrials.gov.
  • 03 May 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top